Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy

Diabetes, Obesity and Metabolism

Volumn 18, Issue 4, 2016, Pages 348-354

  Polidori, D ^a   Capuano, G ^b   Qiu, R ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Canagliflozin; Initial combination therapy; Metformin; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; CANAGLIFLOZIN PLUS METFORMIN; HEMOGLOBIN A1C; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADMINISTRATION AND DOSAGE; ADULT; ADVERSE EFFECTS; AGED; ALGORITHM; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EXERCISE; FEMALE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; THERAPEUTIC USE;

ADULT; AGED; ALGORITHMS; CANAGLIFLOZIN; COMBINED MODALITY THERAPY; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DIET, DIABETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXERCISE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MODELS, BIOLOGICAL; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84959907911     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12615     Document Type: Article

References (13)

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-149.
2. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012; 66: 446-456.
3. DeFronzo RA, Lewin A, Patel S et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015; 38: 384-393.
4. Rosenstock J, Inzucchi SE, Seufert J, Fleck PR, Wilson CA, Mekki Q. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care 2010; 33: 2406-2408.
5. Rosenstock J, Hansen L, Zee P et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015; 38: 376-383.
6. Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 611-622.
7. Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab 2014; 16: 613-621.
8. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-1987.
9. Williams-Herman D, Johnson J, Teng R et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009; 25: 569-583.
10. Williams-Herman D, Johnson J, Teng R et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 442-451.
11. Rosenstock J, Chuck L, Gonzalez-Ortiz M et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve type 2 diabetes. Diabetes Care 2016. doi:10.2337/dc15-1736.
12. Matthaei S, Catrinoiu D, Celinski A et al. A randomized, double-blind trial of saxagliptin add-on to dapagliflozin + metformin. Diabetes 2015; 64(Suppl. 1): A27.
13. Mathieu C, Ranetti AE, Li D et al. A randomized, double-blind, phase 3 trial of dapagliflozin add-on to saxagliptin + metformin in type 2 diabetes. Diabetes 2015; 64(Suppl. 1): A28.